Firebrick Pharma (ASX:FRE) received firm commitments to raise AU$1.4 million through the issue of 22 million shares at AU$0.063 apiece, according to a Tuesday filing with the Australian bourse.

Participants will receive one free attaching option for every two shares issued, with an exercise price of AU$0.095 and an expiry date of July 4, 2028, the filing said.

The proceeds will be used to expand Nasodine sales in the US, expand distribution and marketing in Singapore, and fund the final development and manufacturing of up to three new Nasodine-brand products for launch in all available markets in fiscal 2026.

The company previously undertook a fundraising seeking AU$1.6 million in June via a placement through Report Card but raised only AU$200,000, per the filing.